Please assess the completion status of the following clinical trial:

Trial Title: Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven diagnosis of colorectal adenocarcinoma~* Diagnosis of metastatic disease~* RAS (NRAS and KRAS exon 2,3 and 4) wild-type in tissue at initial diagnosis~* Efficacy of a first line therapy containing an anti-EGFR agent (panitumumab or ceuximab) with a major response achieved (complete or partial response)~* Progression after a second line therapy~* Available and adequate baseline tumour tissue sample~* Measurable disease according to RECIST criteria v1.1~* Male or female patients \> 18 years of age~* ECOG Performance Status 0-1~* Life expectancy of at least 3 months~* Adequate bone marrow, liver and renal function~* If female and of childbearing potential, have a negative result on a pregnancy test performed a maximum of 14 days before initiation of study treatment~* If female and of childbearing potential, or if male, agreement to use adequate contraception (eg, abstinence, intrauterine device, oral contraceptive, or double-barrier method)~* Signed informed consent~Exclusion Criteria:~* Any contraindication to use Trifluridine - Tipiracil or Panitumumab~* More than two previous lines of treatment~* Active uncontrolled infections~* Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix~* Pregnancy~* Breastfeeding~* Interstitial lung disease or pulmonary fibrosis~* Grade III or IV heart failure (NYHA classification)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Trifluridine-Tipiracil
- Arm B (Type: EXPERIMENTAL): Panitumumab + Trifluridine-Tipiracil

Based on this trial design, predict the completion outcome and termination type (if applicable).